cencora

Bringing us together or pushing us apart

ISPOR CORPORATE PARTNER 2025

Will JCA, HEMA, and other cross-border collaboration initiatives improve patient access?

ISPOR Educational Symposium May 14, 2025

Our expert panel

Jon Campbell, PhD Speaker

Chief Science Officer, National Pharmaceutical Council



Michael Drummond, DPhil Speaker

Professor Emeritus, University of York Centre for Health Economics



Eldon Spackman, PhD Speaker

Associate Professor, University of Calgary O'Brien Institute for Public Health



Erika Wissinger, PhD Moderator

Senior Director, Market Access & Healthcare Consulting Cencora

Disclaimer: The information provided in this presentation does not constitute legal advice. Cencora strongly encourages the audience to review available information related to the topics discussed during the presentation and to rely on their own experience and expertise in making decisions related thereto.

Poll question



Which of the following most closely describes your organization?

- Academia
- Pharmaceutical and/or device manufacturer
- Healthcare consulting
- Government and/or healthcare policy group
- Other

Today's topics


- Introduction to cross-border HTA collaboration
- Collaboration for sharing workload
- Collaboration for sharing methods
- Collaboration for sharing intelligence - the Canadian experience
- Conclusions



Introduction to cross-border HTA collaboration


Why do we need cross-border collaboration in HTA?

- Health technology assessment (HTA) agencies share the common goal of enabling patient access to new treatments
- However, HTA evaluations of value and benefit vary greatly across markets/countries:
 - Differing evaluation processes
 - Varied methods to determine value/benefit
 - Individual guidelines for how to apply benefits (eg, weighting, thresholds) resulting in highly divergent pricing and reimbursement decisions



How do these approaches to HTA impact patient access?

Differing methodology and appraisal criteria for HTA results in wide variation in availability of treatments across Europe



Cross-border collaborations for HTA – broad aims

Sharing workload and coordinated assessment (equitable access across members)

- EC HTAR (JCA): European Commission HTA regulation (Joint Clinical Assessment)
- JNHB: Joint Nordics HTA-Bodies

Sharing methods, innovation, and best practices

· HEMA: Health Economics Methods Advisory initiative

Sharing intelligence and information (alignment of frameworks, horizon scanning)

- Confidentiality of Clinical Evidence Informing HTA
 Decision-Making position statement
- BeNeLuxAlr: Belgium, Netherlands, Luxembourg, Austria, Ireland



Joint Nordic HTA-Bodies (JNHB)

Successful cross-border HTA collaboration

- Formerly FINOSE, re-launched as ٠ the JNHB in June 2024
- Joint assessments include clinical ٠ efficacy and relevant economic evaluation components
- Aim is to accelerate availability • of new medicines through collaboration
- 4 assessments conducted since • June 2024
 - Focus on oncology and rare . disease
 - Mean assessment time: 82 days ٠



JNHB members include:

- Danish Medicines Council (DMC)
- Finnish Medicines Agency (Fimea)
- National University Hospital of • Iceland (Landspitali)
- Norwegian Medicines Products Agency (NOMA)
- Swedish Dental and Pharmaceutical Benefits Agency (TLV)

What is the Joint Clinical Assessment (JCA)?

New EU-wide HTA process; a single clinical assessment occurring in parallel with the European Medicines Agency (EMA) marketing authorization process

- Integral part of the EU HTA Regulation
- Focus is on relative effectiveness; price & economics are out of scope
- Reliant solely on the review of the manufacturers evidence submission
- High level of transparency expected in final public report
- Legally non-binding, but countries expected to give "due consideration" to its conclusions

Overall aims of the process are to:



Harmonize processes and evidence requirements




Avoid duplication of dossier development for manufacturers



Accelerate patient access across its member states ("solidarity")

What is the process & submission requirements?

Overall process, from initiation to publication of the JCA, is expected to take 13 months; endorsement of the final report is expected 30 days after EMA approval




Key: CHMP – Committee for Medicinal Products for Human Use; CG – (member states) coordination group; EC – European Commission; EUnetHTA – European Network for Health Technology Assessment; HTA – health technology assessment; JCA – Joint Clinical Assessment; PICO – population, intervention, comparator, outcomes.

^a Time zero (T0), months = date of CHMP opinion.

Based on new medical entity, assuming average regulatory timelines. Representative of published timelines by EUnetHTA in July 2023. https://www.eunethta.eu/wp-content/upbads/2023/07/July-13-HTD-meeting-D5.1-and-D5.4.pdf

What is the process & submission requirements?

Defining the scope of the JCA entails surveying all 27 member states of the EU on what population, intervention, comparators and outcomes (PICOs) should be addressed by the procedure



No industry input

What is the health economics methods advisory (HEMA) initiative?

International working group created to foster collaborative, independent research into new health economic methods and processes for HTA

- Canada's Drug Agency (CDA-AMC); USbased Institute for Clinical and Economic Review (ICER); England's National Institute for Health and Care Excellence (NICE)
- Focus is on methods (potential benefits, limitations, and uncertainties, novel methods, suggestions for future research)
- First topic (March 2025): What treatment benefits are appropriate to consider in HTA decision-making?

Overall aims of the process are to:



Examine pressing topics from independent perspective

[,]	

Provide guidance and recommendations for HTA community



Coordinate the development of publications

Confidential

5/12/20 25

How is HEMA structured?



International collaboration focused on theoretical research and practical application of HTA methods

Organized into a Working Group and a **Steering Committee**

Explicit goal of including diverse perspectives, experience, and geographies

to inform HTA decision-making



Includes representation from patient organizations, academic institutions, pharmaceutical and life sciences groups, payers, and policy groups across Canada, UK, and US





Member working group



Steering Committee quides the selection and prioritization of research topics



cencora

Poll question



How do you think cross-border collaboration will impact patient access to new therapies?

- Large positive effect
- Small positive effect
- No/very limited effect
- Small negative effect
- Large negative effect
- Unsure/don't know



Collaboration for Sharing Workload and Facilitating Patient Access

Michael Drummond, DPhil

Professor Emeritus Centre for Health Economics University of York, UK



What are the main challenges? (1)

Depending on the diversity of the jurisdictions, the current standard of care may vary

Different decision-makers may have different preferences for various clinical and patient-reported outcomes

Taken together, these considerations may imply a large number of PICOs* to be examined¹

In the context of JCAs, the EU HTA Coordinating Group (HTA CG) is keen to keep the number of PICOs to a manageable level

* PICO = Population, intervention, comparator, outcome

What are the main challenges? (2)

Decision-makers in different jurisdictions may have different views on the validity or relevance of elements of the analysis

These include, but are not confined to:

- the validity of various types of clinical studies (eg, RCTs vs others)
- the role and use of real-world evidence
- the validation of surrogate outcomes
- evidence synthesis: direct and indirect comparisons
- the relevance of patient reported outcomes

Some of these issues can be handled in joint assessments by using sensitivity analysis

In the context of JCAs, the Member State Coordinating Group of HTA (HTA CG) has issued guidance on many of these topics

What does it mean for the pharmaceutical industry?

Manufacturers are only required to submit their core clinical evidence once, rather than multiple times to different HTA bodies

However, manufacturers will still need to engage with the different HTA bodies' local processes and procedures, which can vary considerably and may have to change to make the best use of the joint assessments¹

In some cases, the analyses conducted for the joint assessment may be sufficient for the HTA body to make a coverage, or reimbursement, recommendation for a new product, but the likelihood of this is currently unclear in the case of JCAs

To meet local decision-making needs, HTA bodies in EU member states are allowed to ask the company for additional data

Those jurisdictions currently requesting economic evaluations may still require companies to submit a dossier containing economic analyses, consistent with their local guidelines

¹Wang T, McAuslane. Ensuring the efficiency and effectiveness of Joint Clinical Assessment in national HTA decision-making: insights from the 2024 CIRS multi-stakeholder workshop. Journal of Market Access and Health Policy 2025;13:9`doi.org/10.3390/jmahp13010009

What's the potential impact on patient access?

It is likely that JCAs will lead to the clinical component of HTAs being completed faster across the EU as whole, offering the potential of earlier patient access

However, the 'economic' component of HTA, including economic modelling and/or price negotiation, remains the responsibility of individual jurisdictions

Depending on the nature of the product and the manufacturer's price expectations, this can be the most difficult and time-consuming part of the HTA process

In addition, jurisdictions can still request the collection of additional data and/or propose managed entry schemes

Although the EU regulation will increase the availability of clinical assessments for more jurisdictions, in many cases the main barrier to patient access remains the jurisdiction's ability or willingness to pay

Overall, the existence of JCAs is unlikely to reduce patient access, but may not increase it very much

Summary

- Collaboration of HTA bodies to share workload makes sense for the resource-intensive tasks in HTA if the results are generalizable across settings
- Collaboration is likely to be more successful if:
 - the current standard of care is similar across settings
 - there is a convergence of views on the key methodological principles
 - the local HTA processes can be adapted to use the results of the joint work effectively

Collaboration for sharing methods


Jon Campbell NPC Chief Science Officer ISPOR Montreal, May 2025



Does Sharing = Caring (As It Relates to HTA Methods and Patient Access)?



How Are HTA Methods & Patient Access Connected?



Good policy sustains appropriate patient access



What Are Examples of Good Methods?

ISPOR Good Practices & Special Task Force for U.S. Value Assessment

Second Panel on Cost-Effectiveness in Health & Medicine

NPC's Guiding Practices for Patient-Centered Value Assessment HTA Inputs: Environmental Context + Science + Judgment Tool, Not Rule



When Are Methods & Patient Access Aligned?



Best practices & methods sharing are transparent



Environment (e.g. supply chain) misaligned incentives are mitigated/minimized



Methods are fit for purpose (priorities vary by jurisdiction)





Challenges Aligning Methods & Patient Access: Judgment Can Influence Methods

A health economist serves on HEMA and receives funding from HTA agencies to co-author report

What outcome is predicted if the health economist and HTA agencies share the position that drug prices are "too high"?

The health economist is assigned to co-write a project on assessing treatment benefits

Predicted outcome: a limited set of treatment benefits are best for inclusion within HTA exercises



Challenges Aligning Methods & Patient Access: Environment & Context Matter

Tomorrow's access can be conditioned on today's access

NPC Research at ASCO: Access to initial and subsequent indications of new oncology drugs: A U.S.-Canada comparison

Today's standard of care becomes tomorrow's therapeutic alternative



Industry Insights on JCA & Patient Access

Unscientific Straw Poll of Industry Members

How do you view the JCA to impact patient access (over 5 years in Europe)?

- 7 votes small (or large) negative impact
- 2 votes neutral or small positive impact

How do you view the JCA to impact patient access (over 20 years, globally)?

- 6 votes small (or large) negative impact
- 3 votes neutral or small positive impact



Summary

We all have a role to play in promoting best practices and good methods!

Be aware — applying good methods in theory & practice

- Judgment and its role in scientific research
- Environment and its role in lumping versus splitting regarding collaborative research

Like any evidence, HTA evidence requires judgment and is specific to its environment suggesting that the findings may be useful tools given the appropriate context (not rules)





Collaboration for sharing information and intelligence

The Canadian experience


Eldon Spackman Associate Professor Faculty of Medicine, Department Community Health Sciences

May 14, 2025

The Canadian Experience: Collaboration to a Point



 Canada's healthcare system is publicly funded and administered, with provincial and territorial governments primarily responsible for its delivery.



The Good

Advantages


- Reduce duplication
- Optimize resource utilization
- Consistency in processes
- Bargaining power?
- Allows for Differences



UNIVERSITY OF

... and the Bad

- Challenges
 - Different context
 - Populations
 - Needs
 - Different systems
 - Different costs



	Canada	N.L.	P.E.I.	N.S.	N.B.	Que.	Ont.	Man.	Sask.	Alta.	B.C.	Yukon	N.W.T.	Nunavut
Life expectancy	6	C	C	C	0	6	A	C	Ð	B	A	0-	0-	0-
Premature mortality	6	6	6	0	ß	A	A	D	D	ß	A	C	0-	0-
Infant mortality	C	0	8	C	0	C	C	0-	0-	D	8	C	0-	0-
Self-reported health	A	A	A	A	A	()+	@ +	@ +	A	@ +	A	A	@+	A
Self-reported mental health	0	A	8	8	0	Ø	A	A	A	A	8	8	₿	D
Mortality due to cancer	8	D	C	0	C	C	B	C	B	A	A	0-	0-	0-
Mortality due to heart disease and stroke	8	C	C	0	6	۵	8	6	6	C	8	6	C	A
Mortality due to respiratory diseases	0	C	C	C	C	0	0	0	0	0	8	D	D	0-
mortality due to	C	0-	8	C	C	8	C	D	D	6	C	0-	0	A +
Mortality due to nervous system diseases	0	6	6	0	6	6	6	6	6	6	0	6	A	A
Suicides	0	0	A	0	0	0	A	B	C	B	0	A	C	0-



International Collaborations



- Health Economics Methods Advisory [HEMA]
- Position statement: Confidentiality of clinical evidence informing health technology assessment decision making



NICE National Institute for Health and Care Excellence



Example: CDA-AMC Therapeutic Review for COPD drugs



Chronic obstructive pulmonary disease in over 16s: diagnosis and management

NICE guideline | NG115 | Published: 05 December 2018 | Last updated: 26 July 2019





- Reduce resources for HTA and manufacturers
 - Could reduce the complexity of thought, if not critical
- Lead to faster decisions
- More consistency

õ

5/12/2025

39

Conclusions

Cross-border collaboration in HTA Summary and conclusions

Benefits

- ✓ Shared (reduced) workload
- ✓ Increased speed to access
- ✓ Alignment/refinement of methods
- Increased transparency and consistency of decision-making

Challenges

- ✓ Local context is key
- ✓ Local decisions on:
 - ✓ Reimbursement
 - ✓ Pricing/cost-sharing
 - ✓ Place in therapy/clinical guidelines and standard of care

Will continue to result in variation across jurisdictions in patient access and outcomes

Poll question



How do you think cross-border collaboration will impact patient access to new therapies?

- Large positive effect
- Small positive effect
- No/very limited effect
- Small negative effect
- Large negative effect
- Unsure/don't know

cencora





Thank you&ज्यवादDěkujeme Mange <mark>takk</mark> Vă mulțumesc<mark>Gracias</mark>Vielen D TeşekkürlerDėkojame jun كان أركش спасибо<u>Merci</u>谢谢<u>Obrigado</u>ありが ざいましたcám on banPaldies감사 Hartelijk dankThank you&ज्यवादDě Mange takkVă multumescGracias Vielen Dank أركش TeşekkürlerD